| Bravo automation of Agilent Avida targeted enrichment for high-throughput detection of genomic alteration and DNA methylation A Wahba, T Ho, S Johns, A Aravind, H Wang, NV Mehendale, GP Amparo, ... Cancer Research 84 (6_Supplement), 2291-2291, 2024 | | 2024 |
| Anti-pd-l1 antibody treatment of bladder cancer J Kurland, JA Blake-Haskins, M Zajac, M Rebelatto, A Gupta, T Ho, ... US Patent App. 17/720,903, 2022 | | 2022 |
| Methods comprising fixed intermittent dosing of cediranib S Barry, J Kendrew, T Ho, S Wedge, IVY Susan, E Kohn, JM Lee | 1 | 2022 |
| Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 M Benton, T Ho, D Kalaitzidis, E Morawa, JA Terrett US Patent App. 17/607,641, 2022 | | 2022 |
| Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 M Benton, T Ho, D Kalaitzidis, E Morawa, JA Terrett US Patent 11,389,481, 2022 | 1 | 2022 |
| Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 M Benton, T Ho, D Kalaitzidis, E Morawa, JA Terrett US Patent App. 17/505,106, 2022 | | 2022 |
| Menetelmät, jotka käsittävät sediranibin kiinteän ajoittaisen annostuksen S Barry, J Kendrew, T Ho, S Wedge, SP Ivy, E Kohn, JM Lee | | 2022 |
| Gene-editing compositions and methods to modulate faah for treatment of neurological disorders SR Police, T Ho, Y Yang, H Chaudhari, A Paldurai US Patent App. 17/407,690, 2022 | | 2022 |
| Fremgangsmåder, som omfatter fast intermitterende dosering af cediranib S Barry, J Kendrew, T Ho, SR Wedge, SP Ivy, E Kohn, JM Lee | | 2022 |
| CTX001 for transfusion-dependent beta-thalassemia (TDT): safety and efficacy results from the ongoing CLIMB THAL-111 study of autologous CRISPR-CAS9-modified CD34 (+ … S Corbacioglu, F Locatelli, S Ailinca-Luchian, Y Bobruff, MD Cappellini, ... ONCOLOGY RESEARCH AND TREATMENT 44, 7-8, 2021 | | 2021 |
| CTX001 for transfusion-dependent β-thalassemia: Safety and efficacy results from the ongoing climb thal-111 study of autologous crispr-cas9-modified cd34+ hematopoietic stem … F Locatelli, S Ailinca-Luchian, Y Bobruff, MD CAPPELLINI, S Corbacioglu, ... Hemasphere 5 (S2), 335-6, 2021 | 12 | 2021 |
| CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply. H Frangoul, TW Ho, S Corbacioglu The New England Journal of Medicine 384 (23), e91-e91, 2021 | 41 | 2021 |
| Toonnote: Improving communication in computational notebooks using interactive data comics DY Kang, T Ho, N Marquardt, B Mutlu, A Bianchi Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems …, 2021 | 37 | 2021 |
| Safety and Efficacy Results with a Single Dose of Autologous CRISPR-Cas9-Modified CD34 (+) Hematopoietic Stem and Progenitor Cells (HSPCs) in Transfusion-Dependent beta … TW Ho, H Frangoul, Y Bobruff, MD Cappellini, S Corbacioglu, ... MOLECULAR THERAPY 29 (4), 64-65, 2021 | | 2021 |
| Early safety and efficacy results with a single dose of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells in transfusion-dependent beta-thalassemia … J de la Fuente, H Frangoul, Y Bobruff, MD Cappellini, S Corbacioglu, ... BRITISH JOURNAL OF HAEMATOLOGY 193, 22-23, 2021 | | 2021 |
| Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia (TDT) or Sickle Cell Disease (SCD): Early Results from the Climb THAL-111 and Climb SCD-121 … S Soni, H Frangoul, Y Bobruff, MD Cappellini, S Corbacioglu, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2021 | | 2021 |
| Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia (TDT) or Sickle Cell Disease (SCD): Early Results from the Climb THAL-111 and Climb SCD-121 … H Frangoul, S Soni, Y Bobruff, MD Cappellini, S Corbacioglu, ... 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021 | | 2021 |
| CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia H Frangoul, D Altshuler, MD Cappellini, YS Chen, J Domm, BK Eustace, ... New England Journal of Medicine 384 (3), 252-260, 2021 | 1484 | 2021 |
| CTX001 for sickle cell disease: safety and efficacy results from the ongoing climb SCD-121 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells S Grupp, N Bloberger, C Campbell, C Carroll, JS Hankins, TW Ho, ... HemaSphere 5, 365, 2021 | 5 | 2021 |
| Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof E Morawa, T Chakraborty, AS Lundberg, T Ho, L Sandler, B Eustace, ... US Patent App. 16/769,926, 2020 | 1 | 2020 |
